Hansa Biopharma AB (STU:24H) FFO per Share

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:24H Hansa Biopharma AB STU:24H
57 GF Score
Price €3.11
GF Value €2.02
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Hansa Biopharma AB FFO per Share?

FFO per Share only applies to REITs.

STU:24H
57GF Score
Hansa Biopharma AB STU:24H
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Hansa Biopharma AB (STU:24H) Overvalued in 2026?

Based on GuruFocus' analysis, Hansa Biopharma AB stock appears to be overvalued. The current stock price of €3.11 is trading 54.2% above its estimated GF Value™ of €2.02. GuruFocus considers Hansa Biopharma AB to be Significantly Overvalued.

Key valuation signals for STU:24H:

  • FFO per Share:
  • GF Value™: €2.02 vs. price of €3.11 (54.2% above fair value)
  • GF Score™: 57/100 with 5 warning signs

No single metric tells the full story. See the STU:24H stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Hansa Biopharma AB Business Description

Address Scheelevagen 22, Lund, SWE, 223 63
Hansa Biopharma AB is a commercial-stage biopharmaceutical company pioneering the development and commercialization of life-saving and life-altering therapies for patients with rare immunological conditions. It has developed a proprietary, first-in-class antibody-cleaving enzyme technology platform designed to eliminate pathogenic IgG antibodies. This differentiated platform supports a broad pipeline with potential applications across Transplantation, Autoimmune diseases, and Gene Therapy-areas characterized by unmet medical need. Hansa's first-generation IgG-cleaving enzyme, imlifidase, is designed to inactivate all four IgG subclasses (IgG1, IgG2, IgG3, and IgG4) in both the intravascular and extravascular compartments following a single intravenous administration.
57GF Score

Get the complete analysis for STU:24H

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.11
Price
€2.02
GF Value